Clinical Trials, Phase II as Topic
"Clinical Trials, Phase II as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries.
| Descriptor ID |
D017322
|
| MeSH Number(s) |
E05.318.760.250.500.210 N05.715.360.775.088.500.210 N06.850.520.450.250.250.210
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase II as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase II as Topic".
This graph shows the total number of publications written about "Clinical Trials, Phase II as Topic" by people in this website by year, and whether "Clinical Trials, Phase II as Topic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Clinical Trials, Phase II as Topic" by people in Profiles.
-
Jamil ML, Deebajah M, Sood A, Alanee S. Combination of pembrolizumab and BCG treatment after endoscopic ablation of high-risk superficial upper urinary tract urothelial carcinoma in patients not candidates for radical nephroureterectomy: protocol for phase-II study. BMJ Open. 2019 12 03; 9(12):e027066.
-
Bratincsak A, Limm-Chan BN, Nerurkar VR, Ching LL, Reddy VD, Lim E, Shohet RV, Melish ME. Study design and rationale to assess Doxycycline Efficacy in preventing coronary Artery Lesions in children with Kawasaki disease (DEAL trial) - A phase II clinical trial. Contemp Clin Trials. 2018 02; 65:33-38.
-
Roytman M, Ramkissoon R, Wu C, Hong L, Trujillo R, Huddleston L, Poerzgen P, Seto T, Wong L, Tsai N. Examining the clinical course of genotype 1 chronic hepatitis C patients treated with the cosmos regimen: including patients with advanced liver disease and East Asian ancestry. Hepatol Int. 2016 Jul; 10(4):616-23.
-
Lammers PE, Horn L. Targeting angiogenesis in advanced non-small cell lung cancer. J Natl Compr Canc Netw. 2013 Oct 01; 11(10):1235-47.
-
Issell BF, Gotay CC, Pagano I, Franke AA. Using quality of life measures in a Phase I clinical trial of noni in patients with advanced cancer to select a Phase II dose. J Diet Suppl. 2009; 6(4):347-59.
-
Hawes D, Liu PY, Muggia FM, Wilczynski S, Cote R, Felix J, Terada K, Belt RJ, Alberts DS. Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary study. Gynecol Oncol. 2002 Oct; 87(1):17-23.
-
Wang WC, Helms RW, Lynn HS, Redding-Lallinger R, Gee BE, Ohene-Frempong K, Smith-Whitley K, Waclawiw MA, Vichinsky EP, Styles LA, Ware RE, Kinney TR. Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. J Pediatr. 2002 Feb; 140(2):225-9.